Unlike other onconeuronal antibodies in PCD (e.g., anti-Hu in SCLC, anti-Yo in ovarian or breast cancer), there is no evidence of immune activity to anti-Tr/DNER antibodies in malignant lymphoma tissue suggesting, that the pathological immune response is not triggered by tumor expression itself but likely from a more complex immune dysregulation caused by the tumor [8]. The gene discussed is CDR2; the disease is lymphoma.